HMGI-C在预测乳腺癌患者表阿霉素治疗疗效中的作用  

Expression of HMGI-C in Prediction of Efficacy of Epirubicin in Treatment of Breast Cancer

作　　者：林道浙[1] 潘升华[1] 庄微雅[1] 薛迪新[1] 陈哈哈 吴伟力[1] 余铭[1] 陈积贤[1] 

机构地区：[1]温州医科大学附属第三医院,瑞安市人民医院,浙江瑞安325200

出　　处：《肿瘤学杂志》2016年第9期733-737,共5页Journal of Chinese Oncology

基　　金：浙江省自然科学基金资助项目(LY14H160043);温州市科技计划项目(Y20130308)

摘　　要：[目的]探讨高迁移率族蛋白HMGI-C在预测乳腺癌患者表阿霉素治疗效果中的作用。[方法]接受表阿霉素新辅助化疗的乳腺癌患者62例,检测其癌组织标本的HMGI-C表达情况,并分析其表达和表阿霉素治疗疗效的关系。[结果]62例乳腺癌患者HMGI-C蛋白总体阳性率为48.4%(30/62);HMGI-C阳性乳腺癌患者表阿霉素治疗有效率显著高于阴性患者(P<0.05);HMGI-C的表达与乳腺癌组织学分级、Ki-67及Her-2呈正相关(P<0.05),与ER及PR呈负相关(P<0.05),与年龄无关。[结论 ]HMGI-C表达情况与乳腺癌患者表阿霉素治疗疗效有密切关系,HMGI-C阳性表达强度越高,患者表阿霉素化疗有效率也越高,可作为预测表阿霉素化疗敏感性的指标。[Objective] To investigate the expression of high mobility group protein（HMGI-C） in predicting the therapeutic effect of epirubicin in breast cancer. [Methods] Sixty-two breast cancer patients receiving neoadjuvant chemotherapy with epirubicin were enrolled in the study. The expression of HMGI-C in cancer tissues was detected by immunohistochemistry and the relationship between HMGI-C expression and therapeutic effect of epirubicin was analyzed. [Results] The overall positive rate of HMGI-C in 62 cases of breast cancer patients was 48.4%（30/62）. HMGI-C positive patients were more sensitive to epirubicin than HMGI-C negative patients（P〈0.05）. The expression of HMGI-C was positively correlated with tumor grade,expressions of Ki-67 and Her-2（P〈0.05）,and negatively correlated with ER and PR（P〈0.05）,but no association was observed with age of patients. [Conclusion] HMGI-C expression is closely related to therapeutic effect of epirubicin in breast cancer,indicating that HMGI-C can be used as a marker for sensitivity to epirubicin of breast cancer.

关 键 词：乳腺肿瘤 HMGI-C 表阿霉素 药物疗法 

分 类 号：R737.9[医药卫生—肿瘤]